Dipna Pharmachem Ltd vs Sai Parenterals Ltd Stock Comparison
Dipna Pharmachem Ltd vs Sai Parenterals Ltd Stock Comparison
Last Updated on: May 05, 2026
Key Highlights
The Latest Trading Price of Dipna Pharmachem Ltd is ₹ 8.07 as of 05 May 15:30
. The P/E Ratio of Dipna Pharmachem Ltd is 0 as of March 2023
.The P/E Ratio of Sai Parenterals Ltd is 0 as of March 2023
. The Market Cap of Dipna Pharmachem Ltd is ₹ 0 crore as of March 2023
.The Market Cap of Sai Parenterals Ltd is ₹ 0 crore as of March 2023
. The Dividend Payout of Dipna Pharmachem Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Sai Parenterals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .
About Dipna Pharmachem Ltd
Dipan Pharmachem Limited was incorporated on July 19, 2011.
Subsequently, the Company name was changed to 'Dipna Pharmachem Private Limited' on March 29, 2012.
Later on, it was converted from Private Limited to Public Limited and the name of Company was changed to 'Dipna Pharmachem Limited' vide fresh Certificate of Incorporation issued by Registrar of Companies, Ahmedabad dated May 25, 2022.
Dipna Pharmachem Limited is a trader, importer, and exporter in industrial Chemical and Pharmaceutical Raw materials, APIs, solvents, and Formulation since 2011.
Presently, its product portfolio comprises of 61 AIPs and AIPs intermediates such as Cephalosporins, Cardiovasculars, Anti - Bactaria, Quinolones, Veterinary, Anti - Virus, Anti - Inflammatory, Neuropsychiatry, Steroid Hormone, other etc.
About Sai Parenterals Ltd
Sai Parenteral's Limited was originally incorporated as Sai Parenteral's Private Limited', a Private Limited Company on January 12, 2001, with the Registrar of Companies, at Hyderabad.
Thereafter, Company was converted into a Public Limited Company and the name of Company was changed to Sai Parenteral's Limited' w.e.f January 17, 2022.
Sai Parenteral's is a diversified pharmaceutical formulations company engaged in the business of Branded Generic Formulations and Contract Development and Manufacturing Organization (CDMO) products and services for the domestic and international markets.
Company has developed a comprehensive and diversified portfolio of complex pharmaceutical products, covering both high-value and high-volume categories addressing critical therapeutic needs across the multiple disease areas.
FAQs for the comparison of Dipna Pharmachem Ltd and Sai Parenterals Ltd
Which company has a larger market capitalization, Dipna Pharmachem Ltd or Sai Parenterals Ltd?
Market cap of Dipna Pharmachem Ltd is 22 Cr while Market cap of Sai Parenterals Ltd is 2,118 Cr
What are the key factors driving the stock performance of Dipna Pharmachem Ltd and Sai Parenterals Ltd?
The stock performance of Dipna Pharmachem Ltd and Sai Parenterals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Dipna Pharmachem Ltd and Sai Parenterals Ltd?
As of May 5, 2026, the Dipna Pharmachem Ltd stock price is INR ₹8.4. On the other hand, Sai Parenterals Ltd stock price is INR ₹479.5.
How do dividend payouts of Dipna Pharmachem Ltd and Sai Parenterals Ltd compare?
To compare the dividend payouts of Dipna Pharmachem Ltd and Sai Parenterals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.